Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 618-939-5 | CAS number: 933999-84-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2-({[6-({1-chloro-3-[(oxiran-2-yl)methoxy]propan-2-yl}oxy)hexyl]oxy}methyl)oxirane; 2-[({6-[(oxiran-2-yl)methoxy]hexyl}oxy)methyl]oxirane; 3-chloro-2-({6-[(oxiran-2-yl)methoxy]hexyl}oxy)propan-1-ol; 6-[(oxiran-2-yl)methoxy]hexan-1-ol
- EC Number:
- 618-939-5
- Cas Number:
- 933999-84-9
- Molecular formula:
- C6H14O2 + C3H5ClO
- IUPAC Name:
- 2-({[6-({1-chloro-3-[(oxiran-2-yl)methoxy]propan-2-yl}oxy)hexyl]oxy}methyl)oxirane; 2-[({6-[(oxiran-2-yl)methoxy]hexyl}oxy)methyl]oxirane; 3-chloro-2-({6-[(oxiran-2-yl)methoxy]hexyl}oxy)propan-1-ol; 6-[(oxiran-2-yl)methoxy]hexan-1-ol
- Details on test material:
- As per IUCLID% Sections 1.1. - 1.4.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Animals were acquired from Charles River U.K. Ltd, Margate, Kent at approximately 6 weeks of age. Animals were housed 5 of the same sex/cage and acclimated 10 days before being placed on study. The animal room conditions were 18-24 degrees C with 36058% relative humidity and a 12 hr light/dark cycle. When not in exposure chambers the aninmals had free access to standard laboratory rat feed (Biosure Diet LAD 1, Biosure, Cambridgeshire, England) and tap water.
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- Animals were exposed whole body to a vapour of the test substance in stainless and glass chamber of approximarely 0.5 m3 volume. The vapor was generated by passing liquid 1,6-Hexanediol Diglycidylether (HDDGE) throught a glass sinter containted in a glass flask by infusion pump. Air at approximately 80 degrees C was passed tthrough this flask. The generated vapor was direct to the inhalations by means of the inlet ducts. Target concentrations were 1, 4 and 16 ug/L. Previuos studies had demonstrated that 16 ug/L 91.8 ppm) was the maximal achievable vapor concentration of HDDGE.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Chamber concentration of HDDGE were determined at 1, 3, and 5 hr of exposure during each exposure. Analysis was by gas chromatography.
- Duration of treatment / exposure:
- 6 h/d, 5 d/w, 4 w
- Frequency of treatment:
- 5 days/week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
16.16 ug/l
Basis:
analytical conc.
- Remarks:
- Doses / Concentrations:
4.04 ug/l
Basis:
analytical conc.
- Remarks:
- Doses / Concentrations:
0.94 ug/l
Basis:
- No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Details on study design:
- Animals were exposed by whole body inhalation. Animals were observed for clinical signs before loading into the inhalation chambers and immediately following unloading. Body weights were taken on a weekly basis during the study. Feed consumption was monitored weekly. Blood samples were withdrawn during study week four for analysis.
- Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- Clinical signs twice a day, feed consumption and body weight weekly, hematology and clinical chemistry once during study week four.
- Sacrifice and pathology:
- At study termination the animals were sacrificed by I. P. injection of pentobarbitone sodium and exsanguniation. During necropsy a detailed macroscopic examination was conducted. The following organs ere taken, trimed and weighted: Thymus, Liver, Adrenals, Lungs, Kidneys and Testes. Tissues removed forr histologiccal examination were preserved in buffered 10% formalin, except the eyes ere fixed in Davidson's fixative. The tissues were stained with hematoxylin and eosin for microscopic examination.
- Statistics:
- Statistical test included: Barlett's one-wat analysis of variance, Kruskal-Wallis, Student's 't' and Williams'.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Minimal inflamation of the nasal tract.
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Greater adrenal weights from high dose was statistically significant for male rats only and considered to not be toxicologically significant.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 4.04 mg/L air (analytical)
- Sex:
- male/female
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 16 mg/m³ air
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Minimal evidence of nasal tract inflammation at the high dose level of 16 mg/m3 with no indication of adverse systemic effects.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Exposure of rats to 1, 4, or 16 ug/L HDDGE for 4 weeks did not have any adverse effect on body weight, clinical sign, hematologic or clinical chemical parameters or gross pathology. An increase in adrenal weights in rats exposed to 16 ug/L HDDGE was unlikely to be of toxicological significance because of the absence of microscopic changes in the adrenals. The only treatment-related microscopic changes were minimal inflamation in the vestibule of the nose and minimal, focal changes in the larynx of rats exposed to 16 ug/L HDDGE for 4 weeks. This is characteristic of a mild irritant. Therefore the systemic NOAEL for this study is > 16 mg/m3 (1.8 ppm). Since this repeated-dose inhalation study failed to achieve a Maximum Toleratd Dose (MTD) it is judged to be unsuitable for the establishment of a systemic DNEL. However, due to histopathological evidence of nasal tract irritation at 16 mg/m3, a local (irrritation) DNEL can be established. Based on E.C.H.A. guidance (E.C.H.A. RIP 3.2, Guidance on information requirements and chemical safety assessment, Chapter R.8) the resulting DNEL values for long-term local (irritation) are Worker = 0.44 mg/m3 (0.047 ppm) and General Population = 0.27 mg/m3 (0.029 ppm).
- Executive summary:
The repeated-dose inhalation toxicity of 1,6 -Hexanediol Diglycidylether (HDDGE) was examined in a 28 -day rat whole body vapor inhaltion study conducted according to O.E.C.D. Testing Guideline No. 412 with GLP compliance. Exposure of rats to 1, 4, or 16 ug/l HDDGE for 4 weeks (5 days/week) did not have any adverse effect on body weight, clinical sign, hematologic or clinical chemical parameters or gross pathology. An increase in adrenal weights in rats exposed to 16 ug/l HDDGE was unlikely to be of toxicological significance because of the absence of microscopic changes in the adrenals. The only treatment-related microscopic changes were minimal inflamation in the vestibule of the nose and minimal, focal changes in the larynx of rats exposed to 16 ug/l HDDGE for 4 weeks. This is characteristic of a mild irritant. Therefore, the systemic NOAEL for this study is > 16 mg/m3 (1.8 ppm). The results from this study demonstrating local, portal-of-entry, nasal tract irritation are appropriate for the derivation of both worker and general population long-term local (irritation) DNELS.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
